Hironic Co Ltd

Hironic Co Ltd maintains a strong liquidity position with a current ratio of 12.95, indicating a significant buffer of current assets over current liabilities. The company's price-to-book ratio of 1.37 and price-to-tangible-book ratio of 1.37 suggest that the market values the company slightly above its book value, while the low debt-to-equity ratio of 0.02 indicates a conservative capital structure with minimal leverage. In terms of profitability, Hironic Co Ltd reports a return on equity (ROE) of 4.98% and a return on assets (ROA) of 4.44%. These figures are below the industry median for ROE and ROA in the Advanced Medical Equipment & Technology sector, suggesting that the company is generating returns at a moderate pace relative to its peers. The company's revenue is primarily derived from the sale of medical and aesthetic devices, with a notable presence in both domestic and overseas markets. However, the financial data does not provide a breakdown of revenue by geographic region or product segment, making it difficult to assess the degree of revenue concentration or diversification. Looking at the growth trajectory, Hironic Co Ltd's revenue for the latest period was reported at 32,086,031,400 KRW, which is slightly higher than the analyst estimate of 31,628,770,000 KRW. The company's free cash flow of 2,404,561,310 KRW indicates a positive cash flow generation, which supports its operational flexibility and potential for reinvestment. The risk assessment for Hironic Co Ltd indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt levels and strong equity position reduce the likelihood of near-term financial distress. Additionally, the absence of dilution risk suggests that the company is not currently issuing new shares at a rate that would significantly impact existing shareholders. Recent events and filings do not highlight any significant changes in the company's operations or financial strategy. The company continues to focus on its core business of manufacturing and selling medical and aesthetic devices, with no major restructuring or strategic shifts reported in the latest financial data.